GeneDx shares soar 25% as exome and genome testing revenue surges 69%

Published 29/07/2025, 11:50
 GeneDx shares soar 25% as exome and genome testing revenue surges 69%

GAITHERSBURG, Md. - On Tuesday, GeneDx Holdings Corp. (NASDAQ:WGS) reported second quarter revenue that substantially exceeded analyst expectations, driven by explosive growth in its core exome and genome testing business.

The genomic testing company’s shares surged 25.27% in pre-market trading after the release.

The company reported second quarter revenue of $102.7 million, marking a 49% increase YoY and significantly beating the analyst consensus of $85.45 million. Adjusted earnings per share came in at $0.50, far surpassing the $0.12 estimate. GeneDx’s exome and genome testing revenue, which represents its core business, jumped 69% YoY to $85.9 million.

"Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx," said Katherine Stueland, CEO of GeneDx. "Our strong second quarter performance was driven by our core business, underscoring its strength and resilience."

The company expanded its adjusted gross margin to 71%, up from 62% in the same quarter last year, while generating adjusted net income of $15 million compared to a $2 million loss in the year-ago period.

Based on the strong performance, GeneDx raised its full-year 2025 guidance, now expecting revenue between $400 million and $415 million, well above the analyst consensus of $369.5 million. The company also increased its forecast for exome and genome revenue growth to 48-52%, up from its previous guidance of 30%.

The results come as the American Academy of Pediatrics recently recommended pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability, potentially expanding GeneDx’s market reach.

The company also completed the acquisition of Fabric Genomics during the quarter, enabling a hybrid centralized and decentralized model for delivering genomic insights globally.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.